The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.

Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD

European journal of pharmacology10 Apr 2010Cited by 30 (Europe PMC)

PMID20385125DOI10.1016/j.ejphar.2010.03.026PepBankPUB-20385125

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine at 1.0 mg/kg produced significant sustained weight loss of 5.7% from baseline.
In plain wordsIn obese rats, tesofensine at 1.0 mg/kg reduced weight by 5.7% from baseline.
Peptide
Tesofensine
Outcome
DecreaseWeight loss at lower dose
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg/kg · oral · 28 daysAs given in this study (rat).
Measurements
Weight loss
5.7%
1.0 mg/kg versus baseline
Source sentences
Summary
Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512501
02AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine at 2.5 mg/kg produced significant sustained weight loss of 9.9% from baseline.
In plain wordsIn obese rats, tesofensine at 2.5 mg/kg reduced weight by 9.9% from baseline.
Peptide
Tesofensine
Outcome
DecreaseWeight loss at higher dose
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
2.5 mg/kg · oral · 28 daysAs given in this study (rat).
Measurements
Weight loss
9.9%
2.5 mg/kg versus baseline
Source sentences
Summary
Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512502
03AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine significantly suppressed food intake, but the effect gradually diminished.
In plain wordsIn obese rats, tesofensine significantly suppressed food intake, but the effect gradually diminished.
Peptide
Tesofensine
Outcome
DecreaseFood intake suppression over time
Study
ratn: not reported in source
Diet-induced obese rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
While all compounds exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512503
04AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine suppressed food intake longer than sibutramine.
In plain wordsIn obese rats, tesofensine suppressed food intake longer than sibutramine.
Peptide
Tesofensine
Outcome
IncreaseFood intake suppression duration
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Sibutramine
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
While all compounds exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512504
05AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine suppressed food intake longer than rimonabant.
In plain wordsIn obese rats, tesofensine suppressed food intake longer than rimonabant.
Peptide
Tesofensine
Outcome
IncreaseFood intake suppression duration
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Rimonabant
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
While all compounds exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512505
06AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, body weight remained reduced with tesofensine, whereas pair-fed rats returned to baseline weight.
In plain wordsIn obese rats, body weight remained reduced with tesofensine, whereas pair-fed rats returned to baseline weight.
Peptide
Tesofensine
Outcome
DecreaseSustained body weight reduction
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Pair-fed rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
In contrast to tesofensine, the body weight of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512506
07AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine was among the treatments that most efficiently reduced abdominal fat mass.
In plain wordsIn obese rats, tesofensine was among the treatments that most efficiently reduced abdominal fat mass.
Peptide
Tesofensine
Outcome
DecreaseAbdominal fat mass
Study
ratn: not reported in source
Diet-induced obese rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
The differential efficacy on weight reduction was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and subcutaneous fat mass which was paralleled by reduced plasma lipid levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512507
08AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine was among the treatments that most efficiently reduced subcutaneous fat mass.
In plain wordsIn obese rats, tesofensine was among the treatments that most efficiently reduced subcutaneous fat mass.
Peptide
Tesofensine
Outcome
DecreaseSubcutaneous fat mass
Study
ratn: not reported in source
Diet-induced obese rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
The differential efficacy on weight reduction was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and subcutaneous fat mass which was paralleled by reduced plasma lipid levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512508
09AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine-associated fat reduction was accompanied by reduced plasma lipid levels.
In plain wordsIn obese rats, tesofensine-associated fat reduction was accompanied by reduced plasma lipid levels.
Peptide
Tesofensine
Outcome
DecreasePlasma lipid levels
Study
ratn: not reported in source
Diet-induced obese rats
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
The differential efficacy on weight reduction was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and subcutaneous fat mass which was paralleled by reduced plasma lipid levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512509
10AnimalAnimal study (in vivo)Efficacy outcome
In obese rats, tesofensine suppressed the plasma insulin response during oral glucose testing below the level achieved by pair feeding.
In plain wordsIn obese rats, tesofensine reduced the insulin response to oral glucose more than pair feeding.
Peptide
Tesofensine
Outcome
DecreaseInsulin response to oral glucose
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Pair feeding
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 28 daysAs given in this study (rat).
Source sentences
Summary
In an oral glucose tolerance test, only tesofensine significantly suppressed the plasma insulin response below the level that could be obtained by paired feeding, indicating that tesofensine further improved glycemic control.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity.
Report a problemFND-2038512510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.